At a glance
- Originator Wakunaga Pharmaceutical
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 02 Jun 1998 Discontinued-Preclinical for Bacterial infections in Japan (PO)
- 25 Oct 1994 Preclinical development for Bacterial infections in Japan (PO)